Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
13 Mai 2024 - 10:47PM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer and autoimmune disease, today
announced the pricing of an underwritten offering
of 37,931,035 shares of its common stock at a price of $2.90
per share. The gross proceeds from this offering are expected to be
approximately $110 million, before deducting the underwriting
discount and commissions and estimated offering expenses payable by
Allogene.
The offering is anchored by mutual funds and large institutional
investors and includes leading healthcare specialists as well as
certain members of the Allogene Board of Directors and Executive
Management Team. The offering is expected to close on or about May
16, 2024, subject to customary closing conditions.
Goldman Sachs & Co. LLC is acting as sole book-running
manager for the offering.
The securities described above are being offered by Allogene
pursuant to a shelf registration statement (including a prospectus)
filed on March 14, 2024 with the Securities and Exchange
Commission (SEC), which was declared effective on April 25,
2024. A final prospectus supplement and accompanying prospectus
relating to the offering will be filed with the SEC and
will be available for free on the SEC's website
at http://www.sec.gov. Copies of the final prospectus
supplement and accompanying prospectus relating to the offering,
when available, may be obtained from: Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, NY
10282, or by telephone at (866) 471-2526, or by email at
prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) products
for cancer and autoimmune disease. Led by a management team with
significant experience in cell therapy, Allogene is developing a
pipeline of “off-the-shelf” CAR T cell product candidates with the
goal of delivering readily available cell therapy on-demand, more
reliably, and at greater scale to more patients.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The press release may, in some cases, use terms
such as "predicts," "believes," "potential," "proposed,"
"continue," "estimates," "anticipates," "expects," "plans,"
"intends," "may," "could," "might," "will," "should" or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Forward-looking statements
include statements regarding the completion and timing of the
offering. Various factors may cause differences between Allogene’s
expectations and actual results as discussed in greater detail in
Allogene’s filings with the SEC, including without limitation in
its Form 10-Q for the quarter ended March 31, 2024 filed on May 13,
2024. Any forward-looking statements that are made in this press
release speak only as of the date of this press release. Allogene
assumes no obligation to update the forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
AlloCAR T is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoEVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
Von Jun 2023 bis Jun 2024